BIXT · Bioxytran, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $225.5K | - | - | $102.5K | $349.5K | - | $51.0K | - | $27.0K | - |
| SG&A | $214.0K | - | $159.1K | $99.5K | $148.8K | - | $153.9K | $441.2K | $446.5K | - |
| Total Operating Expenses | $1.93M | - | $496.0K | $224.1K | $515.1K | - | $346.2K | $609.4K | $783.8K | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($1.93M) | - | ($496.0K) | ($224.1K) | ($515.1K) | - | ($346.2K) | ($609.4K) | ($783.8K) | - |
| Interest Expense | $35.7K | - | $17.8K | $30.1K | $26.4K | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($2.07M) | - | ($282.7K) | $35.4K | ($1.35M) | - | ($392.4K) | ($661.7K) | ($800.3K) | - |
| EPS - Basic | ($0.02) | - | $0.00 | $0.00 | ($0.02) | - | $0.00 | $0.00 | $0.00 | - |
| EPS - Diluted | ($0.02) | - | $0.00 | $0.00 | ($0.02) | - | $0.00 | $0.00 | $0.00 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $463.0K | $509.9K | $14.5K | $3.1K | $4.3K | $5.2K | $34.7K | $13.5K | $10.0K | $26.1K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $463.0K | $513.5K | $14.5K | $3.1K | $4.3K | $5.2K | $34.7K | $13.5K | $10.0K | $26.1K |
| Total Assets | $615.3K | $658.6K | $156.3K | $147.5K | $136.1K | $138.7K | $159.0K | $128.6K | $125.5K | $137.6K |
| Current Liabilities | $5.01M | $3.25M | $3.06M | $2.78M | $2.84M | $1.93M | $1.24M | $1.23M | $1.12M | $3.25M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $5.01M | $3.25M | $3.06M | $2.78M | $2.84M | $1.93M | $1.24M | $1.23M | $1.12M | $3.25M |
| Stockholders' Equity | ($4.39M) | ($2.59M) | ($2.90M) | ($2.64M) | ($2.71M) | ($1.79M) | ($1.08M) | ($1.10M) | ($990.4K) | ($3.11M) |
| Retained Earnings | ($23.11M) | ($21.04M) | ($20.52M) | ($20.24M) | ($20.27M) | ($18.92M) | ($18.30M) | ($16.96M) | ($16.30M) | ($15.50M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($238.6K) | - | - | - | ($167.3K) | - | - | - | ($75.6K) | - |
| Investing Cash Flow | ($9.2K) | - | - | - | ($15) | - | - | - | ($6.0K) | - |
| Financing Cash Flow | $201.0K | - | - | - | $166.5K | - | - | - | $65.5K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -336.3% | - | -180.9% | 24.0% | -994.9% | - | -246.8% | -514.7% | -637.5% | - |
| Return on equity | 47.1% | - | 9.7% | -1.3% | 50.0% | - | 36.2% | 60.2% | 80.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.09 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.01 | 0.01 | 0.01 |
| Quick ratio | 0.09 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.01 | 0.01 | 0.01 |
| Cash ratio | 0.09 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.01 | 0.01 | 0.01 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -54.1x | - | -27.8x | -7.4x | -19.5x | - | - | - | - | - |
| Equity multiplier | -0.14 | -0.25 | -0.05 | -0.06 | -0.05 | -0.08 | -0.15 | -0.12 | -0.13 | -0.04 |
| Liabilities / Assets | 8.14 | 4.93 | 19.58 | 18.87 | 20.90 | 13.92 | 7.82 | 9.56 | 8.89 | 23.61 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -275.2% | - | -43.3% | 63.2% | 34.3% | - | 64.9% | 40.4% | -4.5% | - |
| Net income growth (YoY) | -52.8% | - | 27.9% | - | -69.1% | - | 60.8% | 53.1% | -1.9% | - |
| EPS growth (YoY) | 0.0% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -62.3% | -44.6% | -167.8% | -139.6% | -173.4% | 42.4% | 49.4% | 58.1% | 75.6% | 5.5% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing BIOXYTRAN against the 5 most active filers in the same SIC group.